Date: 2012-03-08
Type of information: Licensing agreement
Compound: LT-02
Company: Dr. Falk Pharma GmbH (Germany) Lipid Therapeutics (Germany)
Therapeutic area: Autoimmune diseases - Inflammatory diseases
Type agreement: licensing
Action mechanism: LT-02 is a delayed release formulation of phosphatidylcholine designed to improve the barrier function of the mucosal layer of the colon.
Disease: ulcerative colitis
Details: Dr. Falk Pharma GmbH and Lipid Therapeutics have entered into a licensing agreement for the European rights to Lipid Therapeutics’ lead product, LT-02, for ulcerative colitis (UC). The terms of the license include an upfront fee, milestones and royalties. Following a co-development and option-agreement in 2009, Dr. Falk GmbH will assume full responsibility for the further development and commercialization of LT-02 in Europe, with a Phase III induction trial in UC planned to start in the second half of 2012. Lipid Therapeutics is currently in discussions with potential development partners in the US.
Financial terms:
Latest news:
